A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) Infection

Inclusion Criteria:

- Male or female (of non-child bearing potential) between 18 and 70 years of age with
Body Mass Index ≥18 to <38 kg/m2.

- Chronic HCV genotype 3 infection prior to study enrollment and has never received
antiviral treatment for HCV.

- Subject has plasma HCV RNA level > 10,000 IU/mL at Screening.

- Sexually active males must be sterile, have male partners only, or agree to use two
effective forms of birth control for 7 months after stopping study drug.

Exclusion Criteria:

- History of severe, life-threatening or other significant sensitivity to any drug.

- Positive test result for Hepatitis B surface antigen (HBsAg) or anti-Human
Immunodeficiency virus antibody (HIV Ab).

- Prior therapy for the treatment of HCV.

- Any current or past clinical evidence of cirrhosis.

- Any cause of liver disease other than chronic HCV-infection.

- HCV genotype co-infection with any other HCV genotype.

- Use of contraindicated medications within 2 weeks or 10 half-lives of dosing.